|
|
| | AZD-5153 HNT salt Basic information |
| Product Name: | AZD-5153 HNT salt | | Synonyms: | AZD5153 (6-Hydroxy-2-naphthoic acid);AZD5153
(API form);AZD515;AZD 5153 6-HYDROXY-2-NAPHTHOIC ACID; AZD-5153 6-HYDROXY-2-NAPHTHOIC ACID;AZD-5153 HNT salt;AZD-5153 HNT SALT;AZD5153;AZD5153 6-Hydroxy-2-Naphthoic Acid salt;Epigenetic Reader Domain,AZD5153 6 Hydroxy 2 naphthoic acid,Inhibitor,AZD5153 6Hydroxy2naphthoic acid,inhibit,AZD-5153,AZD-5153 HNT,AZD 5153,AZD-5153 6-Hydroxy-2-naphthoic acid | | CAS: | 1869912-40-2 | | MF: | C36H41N7O6 | | MW: | 667.77 | | EINECS: | | | Product Categories: | | | Mol File: | 1869912-40-2.mol |  |
| | AZD-5153 HNT salt Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:67.0(Max Conc. mg/mL);200.67(Max Conc. mM)
Ethanol:27.0(Max Conc. mg/mL);40.43(Max Conc. mM) | | form | Solid | | color | White to off-white |
| | AZD-5153 HNT salt Usage And Synthesis |
| Uses | AZD5153 (6-Hydroxy-2-naphthoic Acid) is a potent triazolopyridazine-based Bromodomain (BRD4) and Extraterminal (BET) inhibitor used in cancer treatments. | | in vivo | Administration of AZD5153 leads to tumor stasis or regression in multiple xenograft models of acute myeloid leukemia, multiple myeloma, and diffuse large B-cell lymphoma. AZD5153 treatment markedly impacts transcriptional programs of MYC, E2F, and mTOR[1]. |
| | AZD-5153 HNT salt Preparation Products And Raw materials |
|